Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.

OBJECTIVE P-glycoprotein (P-gp) of membrane transporters leads to drug resistance by the exclusion of intracellular drugs, including corticosteroids. Some patients with highly active systemic lupus erythematosus (SLE) show poor response to corticosteroids; however, the mechanisms of steroid resistance remain unclear. The aim of this study was to elucidate the clinical relevance of P-gp expression on lymphocytes to steroid resistance in patients with active SLE. METHODS Flow cytometric analyses of the expression of P-gp on peripheral blood lymphocytes from 20 normal volunteers and 80 SLE patients were performed. Steroid-exclusion analysis of peripheral blood mononuclear cells (PBMCs) was conducted by using radioisotope-labeled dexamethasone. RESULTS P-gp was expressed at significantly high levels on most of the peripheral blood lymphocytes from SLE patients, whereas normal lymphocytes had only marginal expression. The quantity of P-gp on SLE lymphocytes correlated with the disease activity in each patient, as estimated by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Furthermore, in SLE patients whose SLEDAI scores were >12 despite taking >0.5 mg/kg/day of prednisolone, P-gp expression on lymphocytes was markedly increased, and intracellular dexamethasone in their PBMCs was significantly decreased. However, intensive immunosuppressive treatment in these SLE patients resulted in successful control of disease activity, which occurred in parallel with a marked reduction of P-gp on lymphocytes. CONCLUSION The overexpression of P-gp on lymphocytes might lead to exclusion of corticosteroids from lymphocytes, resulting in steroid resistance in patients with highly active SLE. Reduction of P-gp expression achieved by intensive immunosuppressive treatment overcame the steroid resistance. We therefore propose that measurement of P-gp expression on lymphocytes is useful in the assessment of steroid resistance and is a good marker for indicating the need for intensive immunosuppressive treatment in patients with highly active SLE.

[1]  Yoshiya Tanaka,et al.  Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus , 2005, Modern rheumatology.

[2]  K. Kohno,et al.  Transcriptional regulation of multidrug resistance‐1 gene by interleukin‐2 in lymphocytes , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[3]  D. Kelleher,et al.  Glucocorticoid resistance in inflammatory bowel disease. , 2003, The Journal of endocrinology.

[4]  F. Lai,et al.  Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. , 2003, Arthritis and rheumatism.

[5]  A. Takeshita,et al.  Putative Role of the Orphan Nuclear Receptor SXR (Steroid and Xenobiotic Receptor) in the Mechanism of CYP3A4 Inhibition by Xenobiotics* , 2002, The Journal of Biological Chemistry.

[6]  M. Slovak,et al.  Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. , 2002, Blood.

[7]  R. Omdal,et al.  Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics. , 2002, The Journal of rheumatology.

[8]  E. Kelly,et al.  IL-2 and Related Cytokines Can Promote T Cell Survival by Activating AKT1 , 2002, The Journal of Immunology.

[9]  E. Baldissera,et al.  Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. , 2000, Rheumatology.

[10]  C. Figdor,et al.  H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. , 1999, Journal of immunology.

[11]  R. Advani,et al.  Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). , 1999, Advances in experimental medicine and biology.

[12]  O. Meijer,et al.  Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. , 1998, Endocrinology.

[13]  L. Yang,et al.  Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. , 1998, British journal of rheumatology.

[14]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[15]  S. Eto,et al.  Distinct phenotype of leukemic T cells with various tissue tropisms. , 1997, Journal of Immunology.

[16]  K. Yoshida,et al.  Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells , 1996, The Journal of experimental medicine.

[17]  G. Giaccone,et al.  p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. , 1996, British Journal of Cancer.

[18]  Costan,et al.  Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.

[19]  Hong Wang,et al.  Cytokine Gene Profile in Circulating Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus: Increased Interleukin-2 but not Interleukin-4 mRNA , 1994, Lupus.

[20]  N. Cooper,et al.  T cell-dependent, B cell-activating properties of antibody-coated small latex beads. A new model for B cell activation. , 1994, Journal of immunology.

[21]  T. Grogan,et al.  P-glycoprotein expression and function in circulating blood cells from normal volunteers. , 1994, Blood.

[22]  J. Riordan,et al.  Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. , 1993, The Journal of biological chemistry.

[23]  S. Bourgeois,et al.  Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. , 1993, Molecular endocrinology.

[24]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[25]  I. Roninson,et al.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.

[26]  P. Dau,et al.  Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. , 1991, The Journal of rheumatology.

[27]  R. Mader,et al.  Malabsorption in systemic lupus erythematosus. , 1990, Clinical and experimental rheumatology.

[28]  S. Eto,et al.  Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus. , 1988, Journal of immunology.

[29]  T. Tsuruo,et al.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. , 1988, Cancer research.

[30]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Tsuruo,et al.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Greco,et al.  [Gastroenterologic aspects of connective tissue diseases]. , 1985, Minerva medica.

[33]  S. Kawai.  [A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. , 1985, Nihon Naibunpi Gakkai zasshi.

[34]  T. Tsuruo.  Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. , 1983, Cancer treatment reports.

[35]  H. Simon,et al.  P-glycoprotein expression in circulating blood leukocytes of patients with steroid-resistant asthma. , 1996, Journal of investigational allergology & clinical immunology.

[36]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[37]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.